A detailed history of Bank Of America Corp transactions in Ardelyx, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,807,108 shares of ARDX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,807,108
Previous 1,042,910 73.28%
Holding current value
$10.5 Million
Previous $7.61 Million 75.88%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.31 $4.5 Million - $7.11 Million
764,198 Added 73.28%
1,807,108 $13.4 Million
Q1 2024

May 15, 2024

BUY
$6.05 - $9.74 $3.53 Million - $5.68 Million
582,951 Added 126.74%
1,042,910 $7.61 Million
Q4 2023

Feb 14, 2024

SELL
$3.29 - $6.64 $6.46 Million - $13 Million
-1,962,151 Reduced 81.01%
459,959 $2.85 Million
Q2 2023

Aug 14, 2023

BUY
$3.23 - $4.95 $1.11 Million - $1.7 Million
343,611 Added 16.53%
2,422,110 $8.21 Million
Q1 2023

May 12, 2023

BUY
$2.68 - $4.79 $5.14 Million - $9.19 Million
1,917,760 Added 1193.09%
2,078,499 $9.96 Million
Q4 2022

Feb 10, 2023

SELL
$1.22 - $2.85 $109,753 - $256,391
-89,962 Reduced 35.88%
160,739 $458,000
Q3 2022

Nov 14, 2022

SELL
$0.59 - $1.44 $7,802 - $19,044
-13,225 Reduced 5.01%
250,701 $298,000
Q2 2022

Aug 12, 2022

SELL
$0.51 - $1.17 $116,657 - $267,625
-228,740 Reduced 46.43%
263,926 $155,000
Q1 2022

May 16, 2022

BUY
$0.65 - $1.18 $292,904 - $531,735
450,623 Added 1071.81%
492,666 $527,000
Q4 2021

Feb 08, 2022

SELL
$0.86 - $1.7 $673,635 - $1.33 Million
-783,297 Reduced 94.91%
42,043 $46,000
Q3 2021

Nov 15, 2021

BUY
$1.27 - $8.17 $998,292 - $6.42 Million
786,057 Added 2001.01%
825,340 $1.09 Million
Q2 2021

Sep 13, 2021

BUY
$6.55 - $8.98 $257,303 - $352,761
39,283 New
39,283 $298,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $895M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.